Zobrazeno 1 - 10
of 881
pro vyhledávání: '"Christoph C Zielinski"'
Autor:
Barbara Kiesewetter, Urania Dafni, Elisabeth G E de Vries, Jorge Barriuso, Giuseppe Curigliano, Veronica González-Calle, Martina Galotti, Bishal Gyawali, Brian Huntly, Ulrich Jaeger, Nicola Jane Latino, Luca Malcovati, Sjoukje Oosting, Gert Ossenkoppele, Martine Piccart, Markus Raderer, Lydia Scarfò, Dario Trapani, Christoph C Zielinski, Ruth Wester, Panagiota Zygoura, Elizabeth Macintyre, Nathan I Cherny
Publikováno v:
HemaSphere, Vol 7, p e02308e3 (2023)
Externí odkaz:
https://doaj.org/article/fbaa6acb8eac44379781acba442210b6
Autor:
Christoph C Zielinski, Markus Kieler, Matthias Unseld, Daniela Bianconi, Fredrik Waneck, Robert Mader, Fritz Wrba, Thorsten Fuereder, Philipp Staber, Walter Berger, Maria Sibilia, Stephan Polterauer, Leonhard Müllauer, Gerald W Prager
Publikováno v:
ESMO Open, Vol 4, Iss 4 (2019)
Background High-throughput genomic profiling of tumour specimens facilitates the identification of individual actionable mutations which could be used for individualised targeted therapy. This approach is becoming increasingly more common in the clin
Externí odkaz:
https://doaj.org/article/a302d32bee064beda7f655065565cb61
Autor:
Christoph C Zielinski
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 3 (2019)
Externí odkaz:
https://doaj.org/article/dc4afffee342496e810f06ba725e1e04
Autor:
Christoph C Zielinski
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/7b577c3b23414c4e82eda45aa6c023fb
Autor:
Daphne Gschwantler-Kaulich, Yen Y Tan, Eva-Maria Fuchs, Gernot Hudelist, Wolfgang J Köstler, Angelika Reiner, Carmen Leser, Mohamed Salama, Johannes Attems, Christine Deutschmann, Christoph C Zielinski, Christian F Singer
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0172911 (2017)
BACKGROUND:Even though trastuzumab is an effective therapy in early stage Her-2+ breast cancer, 40-50% of advanced Her-2+ breast cancer patients develop trastuzumab resistance. A potential resistance mechanism is aberrant downstream signal transmissi
Externí odkaz:
https://doaj.org/article/20f11d17673548958991b9d8d5432c0a
Autor:
Christian Rolfo, Christoph C Zielinski
Publikováno v:
Annals of Thoracic Medicine, Vol 12, Iss 4, Pp 219-220 (2017)
Externí odkaz:
https://doaj.org/article/551cb6a1de074a2f9bdb89e989c002e5
Autor:
Werner Haslik, Ursula Pluschnig, Günther G Steger, Christoph C Zielinski, K F Schrögendorfer, Jakob Nedomansky, Rupert Bartsch, Robert M Mader
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103649 (2014)
BACKGROUND: Extravasation of cytotoxic drugs is a serious complication of systemic cancer treatment. Still, a reliable method for early assessment of tissue damage and outcome prediction is missing. Here, we demonstrate that the evaluation of blood f
Externí odkaz:
https://doaj.org/article/3d4e8cd926544a66b5009281b62119b0
Autor:
Angelika Wagner, Erika Garner-Spitzer, Claudia Auer, Pia Gattinger, Ines Zwazl, René Platzer, Maria Orola-Taus, Peter Pichler, Fabian Amman, Andreas Bergthaler, Johannes B. Huppa, Hannes Stockinger, Christoph C. Zielinski, Rudolf Valenta, Michael Kundi, Ursula Wiedermann
Publikováno v:
Vaccines, Vol 12, Iss 5, p 518 (2024)
Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2 vaccination. The effects of booster vaccinations and breakthrou
Externí odkaz:
https://doaj.org/article/26083936ad8646f7a8062db04cd5010d
Autor:
Joshua Tobias, Sandra Högler, Martin Raigel, Diego Shih-Chieh Lin, Yee Chao, Lukas Kenner, Erika Garner-Spitzer, Sharon Yavrom, Nicholas J. Ede, Christoph C. Zielinski, Michael Kundi, Ursula Wiedermann
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 287 (2023)
Her-2/neu-targeting therapy by passive application with trastuzumab is associated with acquired resistance and subsequent metastasis development, which is attributed to the upregulation of tumoral PD-L1 expression and the downregulation of Her-2/neu.
Externí odkaz:
https://doaj.org/article/bec8d8a4bc6f4924bd71e225660cc70c
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK